Out of 3 analysts covering Aeterna Zentaris Inc. (NASDAQ:AEZS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $12.0 is the highest target while $11 is the lowest. The $11.50 average target is 234.30% above today’s ($3.44) stock price. Aeterna Zentaris Inc. has been the topic of 4 analyst reports since November 9, 2015 according to StockzIntelligence Inc. H.C. Wainwright maintained the stock on December 2 with “Buy” rating. Below is a list of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) latest ratings and price target changes.
About 83,727 shares traded hands. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) has risen 20.00% since February 8, 2016 and is uptrending. It has outperformed by 3.51% the S&P500.
Aeterna Zentaris Inc. is a specialty biopharmaceutical firm engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The company has a market cap of $33.49 million. The Firm operates through the biopharmaceutical segment. It currently has negative earnings. The Firm is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.